Nutex Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NUTX research report →
Range $310 – $336
Price Chart
About the company
Nutex Health, Inc. functions as a technology-powered enterprise delivering healthcare services, structured into two key segments: its Hospital division and its Population Health Management division. The Hospital division is tasked with developing and overseeing various healthcare models, encompassing micro-hospitals, specialized medical centers, and hospital outpatient facilities.
- CEO
- Thomas T. Vo
- IPO
- 2022
- Employees
- 1,037
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on NUTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.12B
- P/E
- 7.31
- Fwd P/E
- 5.90
- PEG
- 0.33
- P/S
- 1.50
- P/B
- 2.74
- EV/EBITDA
- 3.94
- Div Yield
- 0.00%
- Gross Margin
- 47.79%
- Op Margin
- 39.04%
- Net Margin
- 20.68%
- ROE
- 43.76%
- ROIC
- 27.07%
Latest fiscal year · YoY change
- Revenue
- $875.26M+82.4%
- Gross Profit
- $444.28M+126.4%
- Op Income
- $275.63M
- Net Income
- $70.79M+35.7%
- EPS
- $11.13+8.8%
- OCF Growth
- +971.6%
- FCF Growth
- +1077.9%
- 52W High
- $226.16
- 52W Low
- $83.99
- 50D MA
- $200.34
- 200D MA
- $152.46
- Beta
- 2.00
- RSI (14)
- 37
- Avg Volume
- 149.27K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Nutex said Q3 showed strong patient-volume growth, solid cash generation and improving reimbursement visibility, even as reported revenue and EBITDA were pressured by comparisons to unusually strong 2025 IDR recognition.· November 6, 2026
- Q3 patient demand stayed strong: hospital visits rose 18.1% and same-hospital visits rose 12.4%.
- Cash and liquidity improved, with cash on hand at $249.9 million and net cash from operating activities of $188.1 million for the first nine months of 2026.
- Management said payer/IDR dynamics are still supportive, with provider-favorable court rulings and CMS audits reinforcing its view of the NSA/IDR framework.
- Two hospitals are expected to open in Q4, with four more projects under construction for late 2027/early 2028.
- Management said 2027 guidance could be provided later this year as reporting becomes more predictable.
For the first nine months of 2026, total revenue was $644.9 million, down 11% from $723.6 million a year ago, and adjusted EBITDA was $211.4 million, down 13% from $243 million. Net income attributable to Nutex rose to $152.9 million from $59 million, while total patient visits increased 10.2% to 154,300 and same-hospital growth was 6.3%. Cash on hand was $249.9 million at September 30, 2026, up from $185.6 million at year-end 2025, and net cash from operating activities was $188.1 million versus $177.7 million last year. For Q3, total revenue was $217.6 million versus $267.8 million in the prior-year quarter. Hospital division revenue was $209.1 million versus $260.2 million, gross profit was $101.5 million or 46.7% of revenue versus $54.9 million or 57.8%, operating income was $77.1 million versus $130 million, net income attributable to Nutex was $40.2 million versus $55.4 million, and adjusted EBITDA attributable to Nutex was $63.9 million versus $98.5 million. Hospital visits in Q3 were 54,622, up 18.1% year over year, and same-hospital visits rose 12.4%. Management said revenue comparisons were skewed by stronger 2025 IDR-driven recognition, and that current revenue per visit has been running around $4,000, with historical average discussion centered around roughly $4,200 and current collections around just over 80%. Forward-looking, management expects two openings in Q4 2026 in San Antonio and Jacksonville, and four additional projects under active construction with expected completion in late 2027 and early 2028. They did not give formal 2027 financial guidance, but said they may begin offering more detail later this year.
Dr. Vo framed the quarter as evidence that Nutex’s model is working on both growth and reimbursement. He emphasized that same-hospital growth matters because it shows expansion is not dependent only on new facilities, and he highlighted continued investments in business development, technology, diagnostics and AI. His tone was confident and supportive of the current reimbursement environment, with strong language in favor of IDR enforcement and against proposals that would eliminate it.
Jon Bates focused on the mechanics behind the year-over-year changes: stronger 2025 IDR-related revenue recognition, a more stable current revenue-per-visit pattern, and improved cost structure after the HALO MD contract renegotiation and lower CMS fees. He cited Q3 hospital division revenue of $209.1 million, gross profit of $101.5 million, and adjusted EBITDA attributable to Nutex of $63.9 million; for the first nine months, gross profit was $334.5 million and adjusted EBITDA attributable to Nutex was $211 million. He also noted cash on hand of $249.9 million, accounts receivable of $356.1 million, and relatively modest bank/equipment debt of about $42.7 million.
Analysts focused on revenue per visit, contract-services expense, cash deployment, payer behavior under the IDR process, and whether Nutex could offer 2027 guidance. Management said contract services should stay in roughly the current range as a percentage of revenue, revenue per visit should remain around the current run-rate if collections stay stable, and the board is discussing capital allocation but still prioritizing hospital openings and growth. On IDR behavior, management said payers are still paying and collections remain around 80% after awards, while provider participation is only slowly improving because the process still takes four to six months and requires cash flow. They also said a more detailed 2027 outlook may be introduced later this year as the business cadence becomes clearer.
The bull case from this call is that volume momentum is strong and broadening across the network, while collections remain solid and cash generation is high. Management also pointed to legal and regulatory developments that it believes strengthen the IDR framework and improve reimbursement visibility over time.
The main risk is that reported revenue and EBITDA remain volatile because prior-year comparisons were boosted by unusually strong IDR recognition, making current-period growth look weaker. Management also flagged potential payer behavior changes, the long and cash-intensive IDR timeline, and possible legislative or regulatory shifts as uncertainties that could affect reimbursement and dispute volume.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 49.4%
- Shares Outstanding
- 6.86M
- Float Shares
- 3.39M
of shares held by institutions
156 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Pertento Partners Llp | 519.19K | ▲ 67.88K |
| Blackrock, Inc. | 394.23K | ▼ 13.12K |
| American Century Companies Inc | 323.84K | ▲ 86.43K |
| Vanguard Group Inc | 258.74K | ▲ 43.79K |
| Vanguard Capital Management LLC | 198.16K | ▼ 17.76K |
| State Street Corp | 135.35K | ▲ 4.51K |
| Geode Capital Management, LLC | 127.19K | ▼ 4.86K |
| D. E. Shaw & Co., Inc. | 97.45K | ▲ 97.45K |
| Ubs Group AG | 81.83K | ▲ 3.92K |
| Winmill & Co. Inc | 65.35K | 0 |
| Empowered Funds, LLC | 56.81K | ▲ 11.63K |
| Millennium Management LLC | 52.11K | ▼ 37.46K |
Held by 242 ETFs
Biggest fund positions in NUTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 26 | Saunders Scott J | sell | 203 |
| Jul 31, 26 | Jaumot Frank E | other | 603 |
| Jul 31, 26 | Grenas Cheryl Yvonne | other | 603 |
| Jul 31, 26 | Saunders Scott J | other | 603 |
| Jul 31, 26 | Reed Michael Lee | other | 603 |
| Jun 4, 26 | Spears Kelvin | other | 2,519 |
| May 28, 26 | Vo Thomas T. | other | 75,747 |
| Apr 23, 26 | Reed Michael Lee | other | 823 |
| Apr 23, 26 | Saunders Scott J | other | 823 |
| Apr 23, 26 | Jaumot Frank E | other | 823 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NUTX coverage
Recent articles, reports, and earnings notes.
No research on NUTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NUTX report →Nutex Health Declares First Dividend as a Public Company
prnewswire.com · Nov 17
NUTX Q3 Earnings Call Highlights Reimbursement and Hospital Growth
zacks.com · Nov 9
Nutex Health Named a 2026 Houston Top Workplace by Houston Chronicle
prnewswire.com · Nov 9
Nutex Health (NASDAQ:NUTX) Shares Gap Down – Time to Sell?
defenseworld.net · Nov 8
Nutex Health Inc. (NUTX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
Nutex Health Q3 Earnings Call Highlights
marketbeat.com · Nov 6
Nutex Health Inc. (NUTX) Q3 Earnings and Revenues Beat Estimates
zacks.com · Nov 5
NUTEX HEALTH REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
prnewswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.